Loading…
Treatment for non-thyroidal illness syndrome in advanced chronic kidney disease: a single-blind controlled study
Aim Non-thyroidal illness syndrome (NTIS) is common among patients with advanced chronic kidney disease (CKD) and is strongly associated with poor prognosis. However, it remains unclear in how to correct this disorder and this study aimed to evaluate the effectiveness of sodium bicarbonate (SB) and...
Saved in:
| Published in: | Journal of nephrology 2017-08, Vol.30 (4), p.557-565 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c344t-782b2f0b2f3b61d6ddc0003e750ee58db8436e0cf0426ac20f16593604fb199a3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c344t-782b2f0b2f3b61d6ddc0003e750ee58db8436e0cf0426ac20f16593604fb199a3 |
| container_end_page | 565 |
| container_issue | 4 |
| container_start_page | 557 |
| container_title | Journal of nephrology |
| container_volume | 30 |
| creator | Yan, Wenjun Wang, Lijuan Huang, Tianlun Xu, Gaosi |
| description | Aim
Non-thyroidal illness syndrome (NTIS) is common among patients with advanced chronic kidney disease (CKD) and is strongly associated with poor prognosis. However, it remains unclear in how to correct this disorder and this study aimed to evaluate the effectiveness of sodium bicarbonate (SB) and N-acetyl-cysteine (NAC) for correcting NTIS status.
Methods
Patients with CKD stage 3–4 were single-blind, placebo-controlled treated with placebo, SB, or NAC for 18 weeks. The primary end points were the correction of NTIS and the occurrence of end-stage renal disease (ESRD). The secondary point was the change in estimated glomerular filtration rate (eGFR) after the follow-up.
Results
The Kaplan–Meier survival analysis showed significant lower correcting ratio of NTIS in control group compared with SB group [Hazard ratio (HR) 0.19, 95 % confidence interval (CI) 0.04–0.89, p = 0.035] and NAC group (HR 0.09, 95 % CI 0.02–0.38, p = 0.001), and increased ESRD risk in control group than in SB group (HR 1.97, 95 % CI 1.02–3.84, p = 0.045) and NAC group (HR 5.50, 95 % CI 2.23–13.57, p |
| doi_str_mv | 10.1007/s40620-016-0341-2 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_s40620_016_0341_2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>27485006</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-782b2f0b2f3b61d6ddc0003e750ee58db8436e0cf0426ac20f16593604fb199a3</originalsourceid><addsrcrecordid>eNp9kM9OwzAMhyMEYjB4AC4oLxBw0jTtuKGJf9IkLuNcpY27ZbTJlHRIfXsyFThysGzJv8-SP0JuONxxgOI-SlACGHDFIJOciRNywQshmYJ8cZpmLjgrpShn5DLGHYDIcyHPyUwUsswB1AXZrwPqoUc30NYH6rxjw3YM3hrdUdt1DmOkcXQm-B6pdVSbL-0aNLTZBu9sQz-tcThSYyPqiA9U02jdpkNWd9almHdD8F2XiDgczHhFzlrdRbz-6XPy8fy0Xr6y1fvL2_JxxZpMyoEVpahFC6myWnGjjGkAIMMiB8S8NHUpM4XQtCCF0o2Alqt8kSmQbc0XC53NCZ_uNsHHGLCt9sH2OowVh-por5rsVcledbRXicTcTsz-UPdo_ohfXSkgpkBMK7fBUO38Ibj0xz9XvwEfwnw3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Treatment for non-thyroidal illness syndrome in advanced chronic kidney disease: a single-blind controlled study</title><source>Springer Nature</source><creator>Yan, Wenjun ; Wang, Lijuan ; Huang, Tianlun ; Xu, Gaosi</creator><creatorcontrib>Yan, Wenjun ; Wang, Lijuan ; Huang, Tianlun ; Xu, Gaosi</creatorcontrib><description>Aim
Non-thyroidal illness syndrome (NTIS) is common among patients with advanced chronic kidney disease (CKD) and is strongly associated with poor prognosis. However, it remains unclear in how to correct this disorder and this study aimed to evaluate the effectiveness of sodium bicarbonate (SB) and N-acetyl-cysteine (NAC) for correcting NTIS status.
Methods
Patients with CKD stage 3–4 were single-blind, placebo-controlled treated with placebo, SB, or NAC for 18 weeks. The primary end points were the correction of NTIS and the occurrence of end-stage renal disease (ESRD). The secondary point was the change in estimated glomerular filtration rate (eGFR) after the follow-up.
Results
The Kaplan–Meier survival analysis showed significant lower correcting ratio of NTIS in control group compared with SB group [Hazard ratio (HR) 0.19, 95 % confidence interval (CI) 0.04–0.89, p = 0.035] and NAC group (HR 0.09, 95 % CI 0.02–0.38, p = 0.001), and increased ESRD risk in control group than in SB group (HR 1.97, 95 % CI 1.02–3.84, p = 0.045) and NAC group (HR 5.50, 95 % CI 2.23–13.57, p < 0.001). The Cox regression analysis demonstrated significantly different effectiveness of placebo, SB and NAC on NTIS correction and ESRD risk, p < 0.05, respectively. Variance analysis displayed a greater reduction in eGFR in controls than in SB (p = 0.044) and NAC group (p < 0.001).
Conclusion
SB and NAC are effective in promoting the recovery from NTIS status and delaying the deterioration of renal function in advanced CKD patients.</description><identifier>ISSN: 1121-8428</identifier><identifier>EISSN: 1724-6059</identifier><identifier>DOI: 10.1007/s40620-016-0341-2</identifier><identifier>PMID: 27485006</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Acetylcysteine - adverse effects ; Acetylcysteine - therapeutic use ; Chi-Square Distribution ; China ; Disease Progression ; Euthyroid Sick Syndromes - diagnosis ; Euthyroid Sick Syndromes - drug therapy ; Euthyroid Sick Syndromes - etiology ; Female ; Glomerular Filtration Rate - drug effects ; Humans ; Kaplan-Meier Estimate ; Kidney - drug effects ; Kidney - physiopathology ; Kidney Failure, Chronic - etiology ; Kidney Failure, Chronic - physiopathology ; Kidney Failure, Chronic - prevention & control ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Nephrology ; Original Article ; Proportional Hazards Models ; Renal Insufficiency, Chronic - complications ; Renal Insufficiency, Chronic - diagnosis ; Renal Insufficiency, Chronic - drug therapy ; Renal Insufficiency, Chronic - physiopathology ; Risk Factors ; Single-Blind Method ; Sodium Bicarbonate - adverse effects ; Sodium Bicarbonate - therapeutic use ; Time Factors ; Treatment Outcome ; Urology</subject><ispartof>Journal of nephrology, 2017-08, Vol.30 (4), p.557-565</ispartof><rights>Italian Society of Nephrology 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-782b2f0b2f3b61d6ddc0003e750ee58db8436e0cf0426ac20f16593604fb199a3</citedby><cites>FETCH-LOGICAL-c344t-782b2f0b2f3b61d6ddc0003e750ee58db8436e0cf0426ac20f16593604fb199a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27485006$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yan, Wenjun</creatorcontrib><creatorcontrib>Wang, Lijuan</creatorcontrib><creatorcontrib>Huang, Tianlun</creatorcontrib><creatorcontrib>Xu, Gaosi</creatorcontrib><title>Treatment for non-thyroidal illness syndrome in advanced chronic kidney disease: a single-blind controlled study</title><title>Journal of nephrology</title><addtitle>J Nephrol</addtitle><addtitle>J Nephrol</addtitle><description>Aim
Non-thyroidal illness syndrome (NTIS) is common among patients with advanced chronic kidney disease (CKD) and is strongly associated with poor prognosis. However, it remains unclear in how to correct this disorder and this study aimed to evaluate the effectiveness of sodium bicarbonate (SB) and N-acetyl-cysteine (NAC) for correcting NTIS status.
Methods
Patients with CKD stage 3–4 were single-blind, placebo-controlled treated with placebo, SB, or NAC for 18 weeks. The primary end points were the correction of NTIS and the occurrence of end-stage renal disease (ESRD). The secondary point was the change in estimated glomerular filtration rate (eGFR) after the follow-up.
Results
The Kaplan–Meier survival analysis showed significant lower correcting ratio of NTIS in control group compared with SB group [Hazard ratio (HR) 0.19, 95 % confidence interval (CI) 0.04–0.89, p = 0.035] and NAC group (HR 0.09, 95 % CI 0.02–0.38, p = 0.001), and increased ESRD risk in control group than in SB group (HR 1.97, 95 % CI 1.02–3.84, p = 0.045) and NAC group (HR 5.50, 95 % CI 2.23–13.57, p < 0.001). The Cox regression analysis demonstrated significantly different effectiveness of placebo, SB and NAC on NTIS correction and ESRD risk, p < 0.05, respectively. Variance analysis displayed a greater reduction in eGFR in controls than in SB (p = 0.044) and NAC group (p < 0.001).
Conclusion
SB and NAC are effective in promoting the recovery from NTIS status and delaying the deterioration of renal function in advanced CKD patients.</description><subject>Acetylcysteine - adverse effects</subject><subject>Acetylcysteine - therapeutic use</subject><subject>Chi-Square Distribution</subject><subject>China</subject><subject>Disease Progression</subject><subject>Euthyroid Sick Syndromes - diagnosis</subject><subject>Euthyroid Sick Syndromes - drug therapy</subject><subject>Euthyroid Sick Syndromes - etiology</subject><subject>Female</subject><subject>Glomerular Filtration Rate - drug effects</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Kidney - drug effects</subject><subject>Kidney - physiopathology</subject><subject>Kidney Failure, Chronic - etiology</subject><subject>Kidney Failure, Chronic - physiopathology</subject><subject>Kidney Failure, Chronic - prevention & control</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Original Article</subject><subject>Proportional Hazards Models</subject><subject>Renal Insufficiency, Chronic - complications</subject><subject>Renal Insufficiency, Chronic - diagnosis</subject><subject>Renal Insufficiency, Chronic - drug therapy</subject><subject>Renal Insufficiency, Chronic - physiopathology</subject><subject>Risk Factors</subject><subject>Single-Blind Method</subject><subject>Sodium Bicarbonate - adverse effects</subject><subject>Sodium Bicarbonate - therapeutic use</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Urology</subject><issn>1121-8428</issn><issn>1724-6059</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kM9OwzAMhyMEYjB4AC4oLxBw0jTtuKGJf9IkLuNcpY27ZbTJlHRIfXsyFThysGzJv8-SP0JuONxxgOI-SlACGHDFIJOciRNywQshmYJ8cZpmLjgrpShn5DLGHYDIcyHPyUwUsswB1AXZrwPqoUc30NYH6rxjw3YM3hrdUdt1DmOkcXQm-B6pdVSbL-0aNLTZBu9sQz-tcThSYyPqiA9U02jdpkNWd9almHdD8F2XiDgczHhFzlrdRbz-6XPy8fy0Xr6y1fvL2_JxxZpMyoEVpahFC6myWnGjjGkAIMMiB8S8NHUpM4XQtCCF0o2Alqt8kSmQbc0XC53NCZ_uNsHHGLCt9sH2OowVh-por5rsVcledbRXicTcTsz-UPdo_ohfXSkgpkBMK7fBUO38Ibj0xz9XvwEfwnw3</recordid><startdate>20170801</startdate><enddate>20170801</enddate><creator>Yan, Wenjun</creator><creator>Wang, Lijuan</creator><creator>Huang, Tianlun</creator><creator>Xu, Gaosi</creator><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20170801</creationdate><title>Treatment for non-thyroidal illness syndrome in advanced chronic kidney disease: a single-blind controlled study</title><author>Yan, Wenjun ; Wang, Lijuan ; Huang, Tianlun ; Xu, Gaosi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-782b2f0b2f3b61d6ddc0003e750ee58db8436e0cf0426ac20f16593604fb199a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acetylcysteine - adverse effects</topic><topic>Acetylcysteine - therapeutic use</topic><topic>Chi-Square Distribution</topic><topic>China</topic><topic>Disease Progression</topic><topic>Euthyroid Sick Syndromes - diagnosis</topic><topic>Euthyroid Sick Syndromes - drug therapy</topic><topic>Euthyroid Sick Syndromes - etiology</topic><topic>Female</topic><topic>Glomerular Filtration Rate - drug effects</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Kidney - drug effects</topic><topic>Kidney - physiopathology</topic><topic>Kidney Failure, Chronic - etiology</topic><topic>Kidney Failure, Chronic - physiopathology</topic><topic>Kidney Failure, Chronic - prevention & control</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Original Article</topic><topic>Proportional Hazards Models</topic><topic>Renal Insufficiency, Chronic - complications</topic><topic>Renal Insufficiency, Chronic - diagnosis</topic><topic>Renal Insufficiency, Chronic - drug therapy</topic><topic>Renal Insufficiency, Chronic - physiopathology</topic><topic>Risk Factors</topic><topic>Single-Blind Method</topic><topic>Sodium Bicarbonate - adverse effects</topic><topic>Sodium Bicarbonate - therapeutic use</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yan, Wenjun</creatorcontrib><creatorcontrib>Wang, Lijuan</creatorcontrib><creatorcontrib>Huang, Tianlun</creatorcontrib><creatorcontrib>Xu, Gaosi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yan, Wenjun</au><au>Wang, Lijuan</au><au>Huang, Tianlun</au><au>Xu, Gaosi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment for non-thyroidal illness syndrome in advanced chronic kidney disease: a single-blind controlled study</atitle><jtitle>Journal of nephrology</jtitle><stitle>J Nephrol</stitle><addtitle>J Nephrol</addtitle><date>2017-08-01</date><risdate>2017</risdate><volume>30</volume><issue>4</issue><spage>557</spage><epage>565</epage><pages>557-565</pages><issn>1121-8428</issn><eissn>1724-6059</eissn><abstract>Aim
Non-thyroidal illness syndrome (NTIS) is common among patients with advanced chronic kidney disease (CKD) and is strongly associated with poor prognosis. However, it remains unclear in how to correct this disorder and this study aimed to evaluate the effectiveness of sodium bicarbonate (SB) and N-acetyl-cysteine (NAC) for correcting NTIS status.
Methods
Patients with CKD stage 3–4 were single-blind, placebo-controlled treated with placebo, SB, or NAC for 18 weeks. The primary end points were the correction of NTIS and the occurrence of end-stage renal disease (ESRD). The secondary point was the change in estimated glomerular filtration rate (eGFR) after the follow-up.
Results
The Kaplan–Meier survival analysis showed significant lower correcting ratio of NTIS in control group compared with SB group [Hazard ratio (HR) 0.19, 95 % confidence interval (CI) 0.04–0.89, p = 0.035] and NAC group (HR 0.09, 95 % CI 0.02–0.38, p = 0.001), and increased ESRD risk in control group than in SB group (HR 1.97, 95 % CI 1.02–3.84, p = 0.045) and NAC group (HR 5.50, 95 % CI 2.23–13.57, p < 0.001). The Cox regression analysis demonstrated significantly different effectiveness of placebo, SB and NAC on NTIS correction and ESRD risk, p < 0.05, respectively. Variance analysis displayed a greater reduction in eGFR in controls than in SB (p = 0.044) and NAC group (p < 0.001).
Conclusion
SB and NAC are effective in promoting the recovery from NTIS status and delaying the deterioration of renal function in advanced CKD patients.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>27485006</pmid><doi>10.1007/s40620-016-0341-2</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1121-8428 |
| ispartof | Journal of nephrology, 2017-08, Vol.30 (4), p.557-565 |
| issn | 1121-8428 1724-6059 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_s40620_016_0341_2 |
| source | Springer Nature |
| subjects | Acetylcysteine - adverse effects Acetylcysteine - therapeutic use Chi-Square Distribution China Disease Progression Euthyroid Sick Syndromes - diagnosis Euthyroid Sick Syndromes - drug therapy Euthyroid Sick Syndromes - etiology Female Glomerular Filtration Rate - drug effects Humans Kaplan-Meier Estimate Kidney - drug effects Kidney - physiopathology Kidney Failure, Chronic - etiology Kidney Failure, Chronic - physiopathology Kidney Failure, Chronic - prevention & control Male Medicine Medicine & Public Health Middle Aged Nephrology Original Article Proportional Hazards Models Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - diagnosis Renal Insufficiency, Chronic - drug therapy Renal Insufficiency, Chronic - physiopathology Risk Factors Single-Blind Method Sodium Bicarbonate - adverse effects Sodium Bicarbonate - therapeutic use Time Factors Treatment Outcome Urology |
| title | Treatment for non-thyroidal illness syndrome in advanced chronic kidney disease: a single-blind controlled study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T11%3A49%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20for%20non-thyroidal%20illness%20syndrome%20in%20advanced%20chronic%20kidney%20disease:%20a%20single-blind%20controlled%20study&rft.jtitle=Journal%20of%20nephrology&rft.au=Yan,%20Wenjun&rft.date=2017-08-01&rft.volume=30&rft.issue=4&rft.spage=557&rft.epage=565&rft.pages=557-565&rft.issn=1121-8428&rft.eissn=1724-6059&rft_id=info:doi/10.1007/s40620-016-0341-2&rft_dat=%3Cpubmed_cross%3E27485006%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c344t-782b2f0b2f3b61d6ddc0003e750ee58db8436e0cf0426ac20f16593604fb199a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/27485006&rfr_iscdi=true |